Investigation Launched on Novozymes A/S and Its Subsidiaries Novozymes Berlin GmbH, Novozymes France S.A.S, Novozymes North America, and Novozymes Enzim Dış Ticaret Ltd. Şti.

Here is a summary of the provided document:

Summary:

On February 8, 2024, the Competition Board decided to conduct a preliminary inquiry into allegations that Novozymes Enzim Du0131u015f Ticaret Ltd.u015eti. (NOVO Tu00dcRKu0130YE) violated the Act no 4054 on the Protection of Competition in the industrial enzymes market. The investigation revealed that Novozymes A/S (NZ) and its subsidiaries, including NOVO Tu00dcRKu0130YE, had a dominant position in the market for fungal alpha amylase enzymes used in the flour and bakery sector. The companies were found to have applied a discount system that created high levels of loyalty among customers and potentially excluded competitors from the market. As a result, the Competition Board launched an investigation under Article 41 of the Act no 4054 to determine if NOVO violated Article 6 of the same Act. An interim measure decision was also taken, prohibiting NOVO from applying discounts or promotions in its sales agreements until the final decision is made.